These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Submaximal Exercise Capacity in Juvenile Dermatomyositis after Longterm Disease: The Contribution of Muscle, Lung, and Heart Involvement. Berntsen KS; Tollisen A; Schwartz T; Kirkhus E; Aaløkken TM; Lund MB; Flatø B; Sjaastad I; Sanner H J Rheumatol; 2017 Jun; 44(6):827-834. PubMed ID: 28365577 [TBL] [Abstract][Full Text] [Related]
8. Lack of achievement of a full score on the childhood myositis assessment scale by healthy four-year-olds and those recovering from juvenile dermatomyositis. Quiñones R; Morgan GA; Amoruso M; Field R; Huang CC; Pachman LM Arthritis Care Res (Hoboken); 2013 Oct; 65(10):1697-701. PubMed ID: 23666925 [TBL] [Abstract][Full Text] [Related]
9. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. II. The Childhood Myositis Assessment Scale (CMAS): a quantitative tool for the evaluation of muscle function. The Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Lovell DJ; Lindsley CB; Rennebohm RM; Ballinger SH; Bowyer SL; Giannini EH; Hicks JE; Levinson JE; Mier R; Pachman LM; Passo MH; Perez MD; Reed AM; Schikler KN; Smith M; Zemel LS; Rider LG Arthritis Rheum; 1999 Oct; 42(10):2213-9. PubMed ID: 10524696 [TBL] [Abstract][Full Text] [Related]
10. Quantitative muscle ultrasound and muscle force in healthy children: a 4-year follow-up study. Jacobs J; Jansen M; Janssen H; Raijmann W; Van Alfen N; Pillen S Muscle Nerve; 2013 Jun; 47(6):856-63. PubMed ID: 23519831 [TBL] [Abstract][Full Text] [Related]
11. Preliminary validation of muscle ultrasound in juvenile dermatomyositis (JDM). Mamyrova G; McBride E; Yao L; Shrader JA; Jain M; Yao J; Curiel RV; Miller FW; Harris-Love MO; Rider LG Rheumatology (Oxford); 2022 Apr; 61(SI):SI48-SI55. PubMed ID: 34791066 [TBL] [Abstract][Full Text] [Related]
12. Long-term muscular outcome and predisposing and prognostic factors in juvenile dermatomyositis: A case-control study. Sanner H; Kirkhus E; Merckoll E; Tollisen A; Røisland M; Lie BA; Taraldsrud E; Gran JT; Flatø B Arthritis Care Res (Hoboken); 2010 Aug; 62(8):1103-11. PubMed ID: 20506141 [TBL] [Abstract][Full Text] [Related]
13. Mycophenolate mofetil in juvenile dermatomyositis: a case series. Dagher R; Desjonquères M; Duquesne A; Quartier P; Bader-Meunier B; Fischbach M; Guiguonis V; Picherot G; Cimaz R Rheumatol Int; 2012 Mar; 32(3):711-6. PubMed ID: 21152922 [TBL] [Abstract][Full Text] [Related]
14. Pulmonary function and autoantibodies in a long-term follow-up of juvenile dermatomyositis patients. Mathiesen PR; Buchvald F; Nielsen KG; Herlin T; Friis T; Nielsen S Rheumatology (Oxford); 2014 Apr; 53(4):644-9. PubMed ID: 24310298 [TBL] [Abstract][Full Text] [Related]
15. Myeloid related protein induces muscle derived inflammatory mediators in juvenile dermatomyositis. Nistala K; Varsani H; Wittkowski H; Vogl T; Krol P; Shah V; Mamchaoui K; Brogan PA; Roth J; Wedderburn LR Arthritis Res Ther; 2013 Sep; 15(5):R131. PubMed ID: 24286299 [TBL] [Abstract][Full Text] [Related]
16. Quantitative muscle ultrasound is a promising longitudinal follow-up tool in Duchenne muscular dystrophy. Jansen M; van Alfen N; Nijhuis van der Sanden MW; van Dijk JP; Pillen S; de Groot IJ Neuromuscul Disord; 2012 Apr; 22(4):306-17. PubMed ID: 22133654 [TBL] [Abstract][Full Text] [Related]
17. Vasculopathy-related clinical and pathological features are associated with severe juvenile dermatomyositis. Gitiaux C; De Antonio M; Aouizerate J; Gherardi RK; Guilbert T; Barnerias C; Bodemer C; Brochard-Payet K; Quartier P; Musset L; Chazaud B; Desguerre I; Bader-Meunier B Rheumatology (Oxford); 2016 Mar; 55(3):470-9. PubMed ID: 26424834 [TBL] [Abstract][Full Text] [Related]
18. Long-term outcome in patients with juvenile dermatomyositis: A case series. Chevalier G; Fakih O; Lhose A; Ballot-Schmit C; Prati C; Puzenat E; Aubin F Arch Pediatr; 2021 Aug; 28(6):475-479. PubMed ID: 34034928 [TBL] [Abstract][Full Text] [Related]
19. Clinical signs and symptoms in a joint model of four disease activity parameters in juvenile dermatomyositis: a prospective, longitudinal, multicenter cohort study. van Dijkhuizen EHP; De Iorio M; Wedderburn LR; Deakin CT; Arthritis Res Ther; 2018 Aug; 20(1):180. PubMed ID: 30111380 [TBL] [Abstract][Full Text] [Related]
20. Expression of myxovirus-resistance protein A: a possible marker of muscle disease activity and autoantibody specificities in juvenile dermatomyositis. Soponkanaporn S; Deakin CT; Schutz PW; Marshall LR; Yasin SA; Johnson CM; Sag E; Tansley SL; McHugh NJ; Wedderburn LR; Jacques TS Neuropathol Appl Neurobiol; 2019 Jun; 45(4):410-420. PubMed ID: 29770465 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]